73.77 USD
↘ 1.19 (1.59%)AT CLOSE (11:59 AM EDT)
Nektar Therapeutics
NKTRNASDAQ • USD
74.34
↗ 0.57 (0.77%)
POST MARKET (AS OF 07:30 PM EDT)
Post Market
AS OF 07:30 PM EDT
74.34
↗ 0.57 (0.77%)
Market: CLOSED
NKTR is currently priced at $73.85. Technicals currently rate "Buy" while our fundamental analysis reads "Neutral". Notable factors include a robust Altman Z-Score, a weak Piotroski F-Score of 2/9, negative Return on Equity, a bullish Golden Cross on the moving averages and bullish moving average alignment. Valuation metrics place NKTR at a fair price relative to peers.
Technical & fundamental data as of Aug 26, 2026.
Open?$74.21
High?$74.97
Low?$73.61
Prev. Close?$74.96
Volume?450.2K
Avg. Volume?655.4K
VWAP?$74.33
Rel. Volume?0.69x
Bid / Ask
Bid?$73.67 × 200
Ask?$75.00 × 200
Spread?$1.33
Midpoint?$74.34
Valuation & Ratios
Market Cap?2.5B
Shares Out?34.1M
Float?28.9M
Float %?97.4%
P/E Ratio?N/A
P/B Ratio?2.79
EPS?-$4.60
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Nektar Therapeutics is a clinical-stage, research-based biopharmaceutical company headquartered in San Francisco, California, and incorporated in Delaware, focused on discovering and developing medicines in the field of immunotherapy. The Company directs its efforts toward creating immunomodulatory agents that selectively induce, amplify, attenuate, or prevent immune responses to achieve desired therapeutic outcomes. Its pipeline of clinical-stage and preclinical-stage immunomodulatory agents targets the treatment of autoimmune diseases, including rezpegaldesleukin, NKTR-0165, NKTR-0166, and NKTR-422, as well as cancer, including NKTR-255.
Themes
Address
455 MISSION BAY BOULEVARD SOUTH
SAN FRANCISCO, CA 94158
Phone: (415) 482-5300
SAN FRANCISCO, CA 94158
Phone: (415) 482-5300
Technical OutlookBuy
Strong SellNeutralStrong Buy
Long-Term (Tide)?▲ Bullish(+2/3)
Medium-Term (Wave)?– Neutral(0/3)
Short-Term (Ripple)?▼ Bearish(-2/3)
MA Alignment?Golden Alignment
Full Technical Analysis →Fundamental OutlookNeutral
Strong SellNeutralStrong Buy
F-Score?12
Z-Score?80
Momentum?71
Short Sent.?39
Piotroski F-Score?2/9Weak
Altman Z-Score?3.31Safe
Confidence?60%Moderate
Short InterestSqueeze Risk
Short % of Float?21.34%Squeeze Risk
Short Interest?6.2M
Days to Cover?10.4
Free Float28.9M
Avg Daily Volume591.7K
Settlement Date2026-08-14
Financial Health
Current Ratio?10.42Strong
Quick Ratio?10.42Strong
Cash Ratio?0.55Adequate
Debt/Equity?0.00Low
ValuationFAIRLY VALUEDvs 1 peers + S&P 500
Score67/100
P/E?N/A▾
P/B?2.79CHEAP▾
Peers100
S&P59
P/S?46.14HIGH▾
Peers100
S&P3
P/FCF?N/A▾
EV/EBITDA?-19.1CHEAP▾
S&P97
EV/Sales?45.42HIGH▾
Peers100
S&P3
Returns & Efficiency
ROE?-17.4%WEAK▾
S&P8
ROA?-14.4%WEAK▾
S&P3
Cash Flow & Enterprise
FCF?$-234032000
Enterprise Value?$2.5B
Fundamentals ratios updated end of day